The 2017 report comes at a time when the international community has acted decisively to achieve consensus on a way forward for joint action.
The purpose of this Technical Brief is to assist Global Fund applicants in their efforts to include and expand programs to remove human rights and gender-related barriers to HIV prevention, diagnosis and treatment services. This Brief discusses the barriers these programs help to remove, the various forms the programs take, the need to cost and allocate budget for them, and how to implement them in effective ways and at appropriate scale. It also aims to help stakeholders ensure that, as they are rolled out, HIV health services and programs promote and protect human rights and gender equality.
The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and
saving lives between 2015 and 2030.
The tool describes how services can be designed and implemented to be accessible and acceptable to people who inject drugs. This requires respectful and ongoing engagement, and this publication gives particular attention to programmes run in close partnership with, or by, organizations of people who use drugs.
HCV prevalence in Asia and the Pacific varies between countries. HCV infection is due to unsterile medical injections (2 , 3) contaminated blood transfusions, (4) traditional cultural practices60 and, more recently, injecting drug use. (5) While iatrogenic transmission still occurs in some countries, transmission as the result of injecting drug use is increasing. (6)
Services to reduce drug-related harms are failing to keep up with growing need, despite pledges to combat AIDS among people who inject drugs.
“The right to life is the foundation of all human rights. The taking of life is irreversible, and goes against our fundamental belief in thedignity and worth of every human being. I call on all world leaders, legislators and justiceofficials to stop executions now. There is no place for the death penalty in the 21st century.” – Ban Ki-moon
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome.
WHO updated its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014.
In this report, the International Drug Policy Consortium (IDPC) offers recommendations based on evidence and examples of good practice to inform a shift in policy responses to drug use in Asia away from criminalization and punishment, and towards public health and harm reduction. It describes effective approaches to the decriminalization of drug use. It also discusses approaches implemented in Asia that have proven ineffective, such as the detention of people who use drugs in compulsory centres as a form of ‘rehabilitation’.